PND22 COMPARISON OF MEDICATION ADHERENCE TO INTERFERON BETA-1B AND INTERFERON BETA-1A SUBCUTANEOUS IN MULTIPLE SCLEROSIS PATIENTS
نویسندگان
چکیده
منابع مشابه
Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...
متن کاملSerum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b.
To verify the possible effect of IFN-beta treatment on auto antibodies development in multiple sclerosis (MS) we studied 69 MS patients before and during the treatment with IFN-beta 1b (n=35) and IFN-beta 1a (n=20) for 27 and 12 months respectively, and, as controls, 14 untreated MS patients. The serum, collected every 3 months from all the patients, was investigated for the presence of antinuc...
متن کاملApplication of Interferon Beta-1b in Multiple Sclerosis
Recombinant interferon beta-1b (IFNβ-1b) was the first approved disease-modifying therapy for patients with multiple sclerosis (MS) by the world regulatory agencies for medical drugs and devices. IFNβ-1b significantly decreases the inflammatory component of MS but still has doubtable effect on the neurodegenerative component. This article appraises the beneficial effects of IFNβ-1b on clinical ...
متن کاملImpact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis
BACKGROUND Adherence to disease-modifying drugs (DMDs) is one of the key factors for achieving optimal clinical outcomes. Rebismart® is an injection device for subcutaneous administration of interferon beta-1a (INF β-1a) that is also able to monitor adherence objectively. The aim of this study was to describe adherence to INF β-1a using the said electronic autoinjection device and to explore th...
متن کاملEfficacy of interferon beta-1a in Iranian multiple sclerosis
Objective: To evaluate the clinical efficacy of onceweekly intramuscular interferon beta-1a (IFN B1a, Avonex Biogen) in Iranian multiple sclerosis (MS) patients. Methods: A 12 months, single blind clinical trial conducted from January 2001 to September 2003. Eighty patients with definite MS age 20 to 50 years were allocated to two groups. The first group received 30 microgram (6MIU) IFN B1a wee...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2009
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)74029-8